Schrodinger Inc is a pioneer in developing a computational platform designed to accelerate the discovery of novel molecules for both drug development and materials applications. With a focus on licensing its groundbreaking software, the company supports the life sciences and materials science industries in transforming molecular discovery. Additionally, Schrodinger is actively involved in drug discovery, working on a portfolio of preclinical and clinical programs on its own and through partnerships. Founded in 1990 and headquartered in New York, it serves a global clientele including biopharmaceutical companies, academic institutions, and government labs.
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
The Pentagon just earmarked over $74 billion for drone dominance and counter drone technologies in the FY2027 budget request, and that is only one slice of the AI arms race AMD and…
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully…
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
This discussion explores secondary opportunities to benefit from the AI boom beyond the most talked about stocks like NVIDIA (NASDAQ: NVDA) | NVDA Price Prediction, Intel (NASDAQ: INTC), or AMD (NASDAQ: AMD).…
